Tg Therapeutics (TGTX) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$23.2 million.
- Tg Therapeutics' Cash from Operations fell 8970.09% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 14949.44%. This contributed to the annual value of -$40.5 million for FY2024, which is 2898.16% down from last year.
- As of Q3 2025, Tg Therapeutics' Cash from Operations stood at -$23.2 million, which was down 8970.09% from $7.4 million recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Cash from Operations peaked at $83.7 million during Q3 2023, and registered a low of -$86.9 million during Q4 2021.
- In the last 5 years, Tg Therapeutics' Cash from Operations had a median value of -$28.7 million in 2025 and averaged -$31.0 million.
- As far as peak fluctuations go, Tg Therapeutics' Cash from Operations soared by 34265.55% in 2023, and later plummeted by 24988.42% in 2025.
- Over the past 5 years, Tg Therapeutics' Cash from Operations (Quarter) stood at -$86.9 million in 2021, then surged by 72.53% to -$23.9 million in 2022, then surged by 44.66% to -$13.2 million in 2023, then tumbled by 94.1% to -$25.6 million in 2024, then grew by 9.7% to -$23.2 million in 2025.
- Its last three reported values are -$23.2 million in Q3 2025, $7.4 million for Q2 2025, and -$28.7 million during Q1 2025.